GlassScriptPhysician profile
Rebecca Dean
NPI 1770145468
$3,497.51
in general payments reported to CMS, 2019-2025
26 companies · $774 in 2025
The $774 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $115 · 2021: $149 · 2022: $700 · 2023: $968 · 2024: $635 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $617.60 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $370.50 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $274.93 | 2021-2025 | Tryptyr, Rocklatan, Total30 |
| Abbvie INC. | $260.47 | 2023-2025 | Durysta |
| Biotissue Holdings INC. | $258.40 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $227.91 | 2022-2024 | Infuse, Miebo |
| Johnson & Johnson Vision Care, INC. | $200.80 | 2019-2024 | Acuvue |
| Oyster Point Pharma, INC. | $195.31 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $194.06 | 2024-2025 | Vevye |
| Dompe US, INC. | $187.53 | 2020-2025 | Oxervate |
| Horizon Therapeutics Plc | $125.10 | 2022-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $94.29 | 2019 | |
| Allergan, INC. | $64.93 | 2019-2021 | |
| Amgen INC. | $55.92 | 2025 | Tepezza |
| Rxsight INC | $54.70 | 2025 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $50.89 | 2020-2022 | |
| Coopervision INC. | $41.23 | 2022-2023 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.31 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $38.08 | 2023 | |
| Aerie Pharmaceuticals, INC. | $29.26 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $27.62 | 2024 | Cirrus Hd-Oct |
| Thea Pharma INC. | $23.55 | 2023 | Iyuzeh |
| Ocular Therapeutix, INC. | $19.82 | 2019 | |
| Glaukos Corporation | $18.36 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.16 | 2024 | Acthar |
| Eyevance Pharmaceuticals LLC | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.